Other content tagged: LRTI
New preliminary study results suggest that new RSV antibody may help reduce infant hospitalisation due to RSV
Interesting first preliminary results from the HARMONIE phase 3b trial on the efficacy of Nirsevimab against RSV (respiratory syncytial virus) infection were presented at the 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Lisbon in early May. According to these initial results, a single intramuscular dose of this new monoclonal antibody would significantly reduce the frequency of hospitalisations in infants with RSV-associated lower respiratory tract infections (LRTI), suggesting that…
Read more
EFCNI Welcomes Platinum Partner AstraZeneca to Raise Awareness of RSV
With EFCNI’s long standing leadership in preterm infants’ health and well-being, and AstraZeneca’s heritage in the RSV space, this partnership aims to increase awareness and educate parents and healthcare providers about the signs and symptoms of this challenging condition and available preventative options. In celebration of EFCNI’s platinum partnership with AstraZeneca, we had the opportunity to sit down with three leaders from AstraZeneca’s RSV team to ask about their work within the disease area. RSV is a very common,…
Read more
